DEF: Conduit Pharmaceuticals Seeks Shareholder Approval for Expanded Equity Plan Amidst Governance Challenges and Strategic Shifts

Conduit Pharmaceuticals Inc. announced its 2025 virtual annual meeting to elect directors, ratify auditors, and approve a significant increase in its stock incentive plan, while detailing recent management changes, related party transactions, and a new licensing agreement with AstraZeneca.

Summary

• The 2025 virtual annual meeting of stockholders will be held on Tuesday, August 5, 2025, at 10:00 a.m., Eastern Time.
• Key proposals for the meeting include the election of five director nominees, the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2025, and the approval of an amendment to the 2023 Stock Incentive Plan to increase the authorized share reserve by an additional 2,000,000 shares.
• As of the record date, July 3, 2025, there were 2,405,140 shares of Common Stock outstanding and entitled to vote.
• The Company effected a 1-for-100 reverse stock split on January 25, 2025, and a 1-for-15 reverse stock split on May 19, 2025.
• Audit reports for the fiscal years ended December 31, 2024, and 2023, contained an explanatory paragraph indicating substantial doubt about the Company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified for fiscal years 2024 and 2023, including limited segregation of duties, lack of formal review processes for significant transactions, recurring errors, and inadequate internal control design.
• Dr. Andrew Regan was appointed Chief Executive Officer in April 2025, succeeding David Tapolczay, who resigned and transitioned to Head of Licensing & Strategy. James Bligh is currently serving as Interim Chief Financial Officer.
• The Company entered into a License Agreement with AstraZeneca AB (PUBL) on August 7, 2024, for HK-4 Glucokinase activators (AZD1656, AZD5658) and myeloperoxidase inhibitor (AZD5904) for idiopathic male infertility, involving a $1.5 million upfront payment and the issuance of 6,336 shares.
• A Joint Development Agreement was signed with Manoira Corporation (controlled by Dr. Regan) on June 3, 2025, for evaluating AZD1656 and AZD5658 in animal health, with the Company issuing 154,799 shares for approximately $500,000 consideration.
• The Company entered into the Sarborg Agreement on December 12, 2024, for algorithmic and cybernetic technology services, with an initial payment of $200,000 cash and 1,515 shares, and potential milestone payments up to $1,800,000. An additional agreement with Sarborg (effective March 31, 2025) for data analysis of AstraZeneca assets involved the issuance of 123,595 shares to satisfy approximately $1.65 million of fees.
• Dr. Regan, through his wholly-owned subsidiary Corvus Capital Limited, engaged in undisclosed loan and pledge agreements in early 2024, resulting in the disposition of approximately 10,000 shares in July 2024, and pledged 20,032 shares to Nirland in August 2024.
• The Company issued a Senior Secured Promissory Note to Nirland for $2,650,000 (inclusive of a $500,000 original issuance discount) on August 6, 2024, bearing 12% interest and maturing on August 5, 2025. An additional $0.6 million promissory note was issued to Nirland on October 28, 2024, bearing 12% interest, which was partially converted and repaid in full on February 12, 2025.

Sentiment

Score: 3

Explanation: The document highlights significant governance and financial control weaknesses, including a 'going concern' warning and undisclosed related party share dealings by the CEO's entity. While there are strategic initiatives like the AstraZeneca license, these are overshadowed by fundamental operational and financial risks. The proposed equity plan, while necessary for incentives, also presents substantial potential dilution. The overall picture suggests a company facing considerable challenges and requiring significant improvements in its internal operations and financial health.

Positives

• A new License Agreement with AstraZeneca for promising pharmaceutical compounds (AZD1656, AZD5658, AZD5904) has been secured, indicating strategic asset acquisition.
• The Company has a strategic focus on development-ready assets and aims to enhance shareholder value.
• The Nasdaq audit committee non-compliance issue was resolved with the appointment of Mr. Fry, restoring compliance with listing standards.
• Stockholders' equity has increased by over $10 million since the adoption of the 2023 Plan.
• The Company successfully raised more than $12 million (net of commission), improving its cash position.
• The newly appointed CEO, Dr. Andrew Regan, continues to waive all Director fees since September 2023, demonstrating a commitment to preserving cash reserves.
• The Board believes its current leadership structure, with separate Chairperson and CEO roles, effectively links management with non-executive oversight.

Negatives

• The independent auditor's report for fiscal years ended December 31, 2024, and 2023, included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, including limited segregation of duties, lack of formal review and approval processes for significant transactions, numerous recurring errors in account balances and disclosures, and inadequate internal controls design.
• The proposed increase of 2,000,000 shares for the 2023 Stock Incentive Plan represents a significant potential dilution, with an overhang of more than 25% on a fully-diluted basis, although grants are capped at 25% of outstanding shares at the grant date.
• Dr. Regan, through his wholly-owned subsidiary Corvus Capital, engaged in loan and pledge agreements without the Company's knowledge, resulting in the disposition of approximately 10,000 shares and the pledging of 20,032 shares to a significant stockholder.
• Two directors, Ms. Jennifer I. McNealey and Ms. Faith L. Charles, resigned due to personal reasons, leading to temporary Nasdaq non-compliance for the audit committee.
• Former Chief Executive Officer David Tapolczay resigned in April 2025, indicating a change in top leadership.

Risks

• Substantial doubt about the Company's ability to continue as a going concern, as explicitly stated in the independent auditor's report, poses a fundamental risk to its long-term viability.
• Material weaknesses in internal control over financial reporting, including limited segregation of duties and a lack of formal review processes, increase the risk of financial misstatements, fraud, and operational inefficiencies.
• The significant potential dilution from the proposed increase in authorized shares for the 2023 Stock Incentive Plan could negatively impact existing shareholder value.
• Related party transactions, particularly those involving Dr. Andrew Regan's entities (Corvus Capital, Manoira, Sarborg) and Nirland, raise concerns about potential conflicts of interest and the fairness of terms.
• The Company's reliance on interim personnel and third-party consultants for critical financial activities due to limited segregation of duties presents operational and control risks.
• Risks associated with the development and commercialization of licensed pharmaceutical products from AstraZeneca, as the Company bears responsibility for these activities, including clinical trial success and regulatory approvals.
• The personal guarantee by Dr. Andrew Regan on the August 2024 Nirland Note links the CEO's personal financial standing to the Company's debt obligations, which could introduce additional complexities.

Future Outlook

The Company aims to utilize the proposed increase in its 2023 Stock Incentive Plan to attract, motivate, and retain high-quality employees, consultants, and directors, aligning their interests with long-term stockholder value creation. It anticipates the new shares requested will last for about 8 years based on historic grant rates and current share price. The Company is primed for strategic licensing, asset acquisitions, and transactions, leveraging its Nasdaq listing and cash reserves.

Management Comments

• Our Board recommends that you vote your shares FOR each of our Boards nominees who are standing for election to our Board (Proposal No. 1), FOR the ratification of the appointment of CBIZ CPAs as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal No. 2), and FOR the approval of an amendment and restatement of our 2023 Plan to increase the authorized share reserve by an additional 2,000,000 shares, in the form attached as Annex A to this proxy statement (Proposal No. 3).
• We believe our future success continues to depend in part on our ability to attract, motivate and retain high quality employees, consultants, and directors and that the ability to provide equity-based and incentive-based awards under the Amended 2023 Plan is critical to achieving this success.
• We would be at a severe competitive disadvantage if we could not use stock-based awards to recruit and compensate our employees and directors.
• The use of common stock as part of our compensation program is also important because equity-based awards continue to be an essential component of our compensation program for key employees, as they help link compensation with long-term stockholder value creation and reward participants based on service and/or performance.
• We recognize that since the adoption of the 2023 Plan Conduit has undergone significant capital structure transformations including the resolution of five Nasdaq deficiencies, transitioned to the Nasdaq Capital Market, increased stockholders equity by over $10m, successfully raised more than $12 million (net of commission) and established itself a Nasdaq-listed, cash-rich vehicle primed for strategic licensing, asset acquisitions, and transactions.
• The Amended 2023 Plan preserves cash reserves at the company, fostering flexibility to capitalize on market opportunities and properly aligns the Board, Executive Management, and employees with the investment interests of our stockholders.
• If the Amended 2023 Plan is not approved, we may be compelled to increase significantly the cash component of our employee and director compensation, which approach may not necessarily align employee and director compensation interests with the investment interests of our stockholders.

Industry Context

Conduit Pharmaceuticals operates in the biopharmaceutical industry, focusing on strategic licensing and asset acquisitions. The recent License Agreement with AstraZeneca for specific compounds (AZD1656, AZD5658, AZD5904) indicates a strategy of acquiring development-ready assets rather than solely relying on internal R&D. This approach can be capital-efficient but relies heavily on successful commercialization of licensed products. The company's emphasis on using equity-based compensation aligns with common practices in the biotech sector to attract and retain talent, especially given the long development cycles and high capital requirements.

Comparison to Industry Standards

• The company's stated 'going concern' issue and material weaknesses in internal controls are significant deviations from industry best practices and raise concerns about financial stability and reporting integrity.
• The proposed equity plan's potential dilution (overhang of over 25%) is high compared to typical industry averages, which often aim for lower single-digit percentages for annual grants, though the 25% grant cap mitigates immediate impact.
• The strategy of licensing assets, such as the agreement with AstraZeneca, is a common approach for smaller biopharmaceutical companies to build a pipeline without the extensive upfront R&D costs of de novo drug discovery, similar to how companies like BridgeBio Pharma or Roivant Sciences operate by in-licensing and developing assets.
• The use of reverse stock splits (1-for-100 and 1-for-15) suggests efforts to maintain Nasdaq listing compliance, a common challenge for smaller companies with declining stock prices, similar to actions taken by other micro-cap biotech firms to avoid delisting.
• The engagement of a proxy solicitation firm (Sodali & Co) for the annual meeting is standard practice for publicly traded companies, especially those with significant proposals or recent corporate changes.

Management Changes

Corporate Governance

Related Party Transactions

• Private Units Transfer: The Sponsor transferred 45,000 private units (15,000 each) to former MURF directors, including current director Ms. Chiavacci Farley, upon the completion of the Business Combination.
• PIPE Subscription Agreement: Corvus Capital Limited (wholly-owned by Dr. Andrew Regan) and its affiliates entered into a participation and inducement agreement with a Private Placement Investor, agreeing to provide certain payments and economic benefits if Corvus Capital sold or pledged shares received in the Business Combination.
• Consulting Agreement with Jack K. Heilbron: Mr. Heilbron, former MURF CEO, President, and Chairman, provides advisory services for $25,000 per calendar quarter and received stock options to purchase 2,000 shares (later 460 shares of common stock).
• Transactions with Corvus Capital Limited: Corvus Capital (wholly-owned by Dr. Andrew Regan, CEO) received 20,765 shares of Common Stock post-Business Combination. As of July 3, 2025, Corvus Capital owns 20,032 shares directly, 118 shares through Algo Holdings, Inc. (wholly-owned subsidiary), and 154,799 shares through Manoira (Corvus owns 99% equity), totaling approximately 7.28% of outstanding shares. Without the Company's knowledge, Dr. Regan, through Corvus Capital, entered into loan and pledge agreements in February-March 2024, resulting in the disposition of approximately 10,000 shares in July 2024. In August 2024, Corvus Capital pledged 20,032 shares (0.83% of outstanding Common Stock as of July 3, 2025) to Nirland, a then significant stockholder, under a participation and inducement agreement that may allow Nirland to cause transfer of shares.
• August 2024 Nirland Note: The Company issued a Senior Secured Promissory Note to Nirland (a related party) for $2,650,000 (inclusive of $500,000 original issuance discount) on August 6, 2024, bearing 12% interest, maturing August 5, 2025. The note is secured by all Company assets and guaranteed personally by Dr. Andrew Regan. Nirland had a right of first refusal for future financings (removed on Oct 31, 2024).
• October 2024 Nirland Note: The Company issued a promissory note to Nirland for $0.6 million on October 28, 2024, bearing 12% interest, maturing October 31, 2025. This note was partially converted and repaid in full on February 12, 2025.
• Transactions with Sarborg Limited: Sarborg (Dr. Regan sits on its board) provides algorithmic and cybernetic technology services for an initial cash payment of $200,000 and 1,515 shares, with potential milestone payments up to $1,800,000. An additional agreement with Sarborg (March 31, 2025) for data analysis of AstraZeneca assets involved the issuance of 123,595 shares to satisfy approximately $1.65 million of fees.
• April 2024 PIPE: The Company issued common stock purchase warrants to third parties, including certain directors, in exchange for lock-up agreements.
• Joint Development Agreement with Manoira Corporation: On June 3, 2025, the Company entered into an agreement with Manoira (controlled by Dr. Regan) for animal health evaluation of AZD1656 and AZD5658, issuing 154,799 shares for approximately $500,000 consideration.
• Directors and Officers: Chele Chiavacci Farley (current director) received 10 shares and 10 redeemable warrants from the Sponsor. Dr. Freda Lewis-Hall (Chairperson) indirectly received 1,335 shares. Dr. David Tapolczay (former CEO) received 1,335 shares. Dr. Andrew Regan (CEO) received 44 shares. James Bligh (Interim CFO) was an employee of Old Conduit. Faith L. Charles (former director) is a partner at Thompson Hine LLP, which provides legal services to the Company.

Stakeholder Impact

• Shareholders: Face potential significant dilution from the proposed equity plan expansion. Exposed to risks associated with the 'going concern' warning and material weaknesses in internal controls, which could impact share price and investment value. Benefit from strategic asset acquisitions (AstraZeneca license) and efforts to enhance shareholder value.
• Employees/Management: Benefit from the expanded equity incentive plan, which aims to attract, motivate, and retain talent through stock options and other awards. Management changes (CEO, CFO) may lead to shifts in strategic direction or operational focus.
• Creditors: The 'going concern' warning and material weaknesses in internal controls could raise concerns about the Company's ability to meet its financial obligations. The Senior Secured Promissory Note to Nirland is secured by all Company assets, providing some protection to that specific creditor.
• Regulatory Authorities (SEC, Nasdaq): The Company has faced and resolved Nasdaq compliance issues related to its audit committee. The delinquent Section 16(a) report by Dr. Regan indicates a need for stricter adherence to regulatory filing requirements. The identified material weaknesses in internal controls are a significant concern for regulatory oversight.

Next Steps

• Hold the 2025 virtual annual meeting of stockholders on August 5, 2025.
• Elect five nominees to serve as directors.
• Ratify the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2025.
• Approve an amendment and restatement to the 2023 Stock Incentive Plan to increase the authorized share reserve.
• File a registration statement on Form S-8 covering shares issuable under the Amended 2023 Plan after stockholder approval.
• Continue development and commercialization of licensed products under the AstraZeneca License Agreement.
• Manoira Corporation to evaluate Conduit Assets applicability in animal health and explore veterinary market opportunities under the Joint Development Agreement.
• Sarborg to provide algorithmic and cybernetic technology services, including data analysis of AstraZeneca assets.

Key Dates

Recommendation

Keywords

Conduit Pharmaceuticals, Proxy Statement, Annual Meeting, Stock Incentive Plan, Equity Compensation, Corporate Governance, Risk Management, Financial Reporting, Internal Controls, Going Concern, Related Party Transactions, AstraZeneca License, Pharmaceutical Development, Reverse Stock Split, Director Election, Auditor Ratification, Nasdaq Compliance, Executive Compensation, Shareholder Meeting